NCT02933866

Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS Topical Product in Patients With Mild to Severe Scalp Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 371 (actual)
• Sponsor: Sun Pharmaceutical Industries, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis

Detailed description

To evaluate the therapeutic efficacy and safety of DSXS topical product (Taro Pharmaceuticals, U.S.A., Inc.) compared to a Vehicle topical product (Taro Pharmaceuticals, U.S.A., Inc.) in patients with mild to severe scalp psoriasis.

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	DSXS topical	topical treatment
DRUG	Vehicle topical	topical treatment

Timeline

• Start date: 2016-03-11
• Primary completion: 2016-11-16
• Completion: 2017-09-29
• First posted: 2016-10-14
• Last updated: 2018-12-06
• Results posted: 2018-12-06

Locations

1 site across 1 country: United States